High-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma

This dataset contains flow cytometry data linked to the publication: High-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma. Allergy. 2025 Jun 26. doi: 10.1111/all.16633 Although the type 2 biologics mepolizumab and dupilumab show clinical efficacy in severe asthma, their influence on circulating lymphocytes is largely unknown. Here, we studied their impact on type 2 lymphocytes in severe asthma. We performed high-parameter flow cytometry analysis of peripheral blood mononuclear cells from 40 patients with severe asthma before (baseline), and after 4 and 12 months of mepolizumab (n =33) or dupilumab (n =7) treatment, focusing on type 2 lymphocytes. Dataset Contents Raw flow cytometry data files. Additional manual compensation adjustments were performed post-acquisition. Manually adjusted compensation matrices (Comp_1, Comp_2, Comp_3, Comp_4) and mapping info, specifying which compensation matrix was used for which sample set. Data Acquisition Notes All longitudinal samples (baseline, 4 months, 1 year) from each patient were analyzed on the same day to minimize batch effects. Flow cytometric data acquisition of all samples was performed using the same compensation setup. Additional manual compensation adjustments were applied post-acquisition to improve downstream analysis quality. Additional Information Full patient characteristics, study inclusion/exclusion criteria, sample processing and storage details, staining protocols and flow cytometry data acquisition details, can be found in the method section of the associated publication. The full flow cytometry panel used for staining is available in the supporting information of the paper (table S1).